Gefitinib in Front-Line Treatment of 161 Caucasian Patients with NSCLC of the Czech Republic

• Autoři: SKŘIČKOVÁ Jana; BORTLÍČEK Zbyněk; HEJDUK Karel; PESEK Milos; KOLEK Vitezslav; KOUBKOVA Leona; CERNOVSKA Marketa; TOMÍŠKOVÁ Marcela; ROUBEC Jaromir; HAVEL Libor; SALAJKA Frantisek; COUPKOVA Helena; HRNCIARIK Michal; ZEMANOVA Milada; SIXTOVA Dimka; ŠATÁNKOVÁ Monika; KADLEC Bohdan; MAREL Miroslav
• Rok publikování: 2015
• Druh: Konferenční abstrakty
• Fakulta / Pracoviště MU: Lékařská fakulta
• Popis: growth factor receptor tyrosine kinase inhibitor. This study evaluates treatment outcomes in 161 NSCLC patients from Czech Republic according to activated mutations located in exons 19 and 21. Conclusion: In both groups of patients, the treatment was very safe. Median PFS and median OS were satisfactory without statistically significant differences between the two groups; however, a better trend was observed in the group of patients with mutations in exon 19. Consequently survival estimates shows great variability and longer potential follow up is needed to confirm these results.